Vaping and lung cancer - A review of current data and recommendations.
Level 5 - mechanism / opinion, no new human data
Narrative literature review focusing on mechanism, chemical toxicology, and in vitro studies with no clinical human outcome data.
PubMed 33429159 · doi:10.1016/j.lungcan.2020.12.030
What was done
The authors conducted a narrative literature review evaluating published research on lung cancer oncogenesis, chemical constituents and pyrolysis products of e-cigarette devices and e-liquids, molecular oncogenic mechanisms, and in vitro cellular effects.
What was found
No quantitative clinical or epidemiological numbers are reported in the abstract. The review notes that e-cigarette devices and e-liquids contain definite and probable oncogens—including nicotine derivatives (nitrosnornicotine, nitrosamine ketone), polycyclic aromatic hydrocarbons, heavy metals, and aldehydes such as formaldehyde formed via glycerol pyrolysis—with documented in vitro cytotoxic and transforming activity.
Why it matters
This paper synthesizes the toxicological and molecular biological plausibility of vaping-related oncogenesis, highlighting the need for regulatory oversight despite the decades-long lag time required to observe clinical lung cancer incidence.
Limits
The review relies on mechanistic and in vitro findings with no human epidemiological or clinical trial data reported in the abstract. Evidence is acknowledged as equivocal, the number of reviewed studies (n) is not specified, and long oncogenic latency prevents immediate direct risk measurement.
Cited by
- supports Vaping aerosols contain byproducts that can produce formaldehyde and are pro-tumor.